A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) f Nanoparticle Vaccine with Aluminium in Healthy Third-trimester Pregnant Woman; and Safet

Project: Other project

StatusActive
Effective start/end date8/18/168/17/21

Funding

  • Novavax Inc: $586,979.68